We found that ErbB3, HER2 and NRG1 expression are particularly widespread in HNSCC, in agreement with other published studies [29,41], and providing a rationale for evaluation of dual ErbB blockage to improve the benefit of cetuximab treatment in this tumor type. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.